1. Inicio
  2. Proyectos y Estudios
  3. A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon).

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon).

Datos básicos

ENSAYO CLÍNICO 20210143 2022-501538-44-00 HOSPITAL DE MANISES Año de incio: 2023

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

AMGEN SA

Compartir